BR112017017608A2 - métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia. - Google Patents

métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.

Info

Publication number
BR112017017608A2
BR112017017608A2 BR112017017608A BR112017017608A BR112017017608A2 BR 112017017608 A2 BR112017017608 A2 BR 112017017608A2 BR 112017017608 A BR112017017608 A BR 112017017608A BR 112017017608 A BR112017017608 A BR 112017017608A BR 112017017608 A2 BR112017017608 A2 BR 112017017608A2
Authority
BR
Brazil
Prior art keywords
schizophrenia
iloperidone
treating
symptom
maintain
Prior art date
Application number
BR112017017608A
Other languages
English (en)
Inventor
D Wolfgang Curt
H Polymeropoulos Mihael
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of BR112017017608A2 publication Critical patent/BR112017017608A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

aspectos da invenção referem-se geralmente ao tratamento de esquizofrenia em um indivíduo e, mais especificamente, ao tratamento de um indivíduo com iloperidona, um metabolito de iloperidona, ou um sal farmaceuticamente aceitável do mesmo. em uma modalidade, a invenção provê um método de prevenção de recaída esquizofrênica em um indivíduo diagnosticado com esquizofrenia, o método compreendendo: administrar iloperidona ao indivíduo, um metabolito de iloperidona, ou um sal farmaceuticamente aceitável do mesmo em uma dose diária de entre cerca de 12 mg e cerca de 16 mg após um período no qual a esquizofrenia do indivíduo foi metabolizada.
BR112017017608A 2015-02-17 2016-02-17 métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia. BR112017017608A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117173P 2015-02-17 2015-02-17
US201562172436P 2015-06-08 2015-06-08
PCT/US2016/018316 WO2016134049A1 (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
BR112017017608A2 true BR112017017608A2 (pt) 2018-05-08

Family

ID=55532275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017608A BR112017017608A2 (pt) 2015-02-17 2016-02-17 métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.

Country Status (10)

Country Link
US (2) US10441580B2 (pt)
EP (1) EP3258935B1 (pt)
JP (1) JP6885649B2 (pt)
KR (1) KR20170118830A (pt)
CN (2) CN116211857A (pt)
BR (1) BR112017017608A2 (pt)
CA (1) CA2976383C (pt)
ES (1) ES2870498T3 (pt)
HK (1) HK1248551A1 (pt)
WO (1) WO2016134049A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504783A (ja) 2001-08-31 2005-02-17 ノバルティス アクチエンゲゼルシャフト イロペリドン代謝産物の光学異性体
JP5067998B2 (ja) 2001-10-30 2012-11-07 ノバルティス アーゲー イロペリドンおよび星形ポリマーのデポー製剤
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA2699786C (en) * 2007-09-10 2019-08-13 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
EA020697B1 (ru) * 2007-12-19 2015-01-30 Янссен Фармацевтика Нв Способ лечения психиатрического пациента путем введения палиперидона пальмитата
ES2533091T3 (es) * 2009-05-15 2015-04-07 Vanda Pharmaceuticals Inc. Tratamiento antipsicótico basado en genotipo de SNP de DRD2 o ANKK1
US20140350029A1 (en) 2011-12-02 2014-11-27 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
AU2013232014B2 (en) 2012-03-14 2016-06-16 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
IL304912A (en) * 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus

Also Published As

Publication number Publication date
CA2976383A1 (en) 2016-08-25
HK1248551A1 (zh) 2018-10-19
EP3258935A1 (en) 2017-12-27
CN107249586A (zh) 2017-10-13
EP3258935B1 (en) 2021-04-07
WO2016134049A1 (en) 2016-08-25
CN116211857A (zh) 2023-06-06
JP6885649B2 (ja) 2021-06-16
CA2976383C (en) 2023-05-23
JP2018505901A (ja) 2018-03-01
KR20170118830A (ko) 2017-10-25
US10441580B2 (en) 2019-10-15
US10987346B2 (en) 2021-04-27
US20180021324A1 (en) 2018-01-25
ES2870498T3 (es) 2021-10-27
US20190388412A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
BR112018003984A2 (pt) anticorpos
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112018008965A8 (pt) terapia de reposição de plasminogênio para deficiência de plasminogênio
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2017000366A (es) Terapia de combinacion para el cancer.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
BR112017006113A2 (pt) combinações sinérgicas de auristatina
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
BR112018009413A2 (pt) formulação oral sólida e método para preparar a formulação oral sólida
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
BR112017017608A2 (pt) métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112017016042A2 (pt) cápsula compósita, e, método para preparar uma cápsula compósita
BR112018002763A2 (pt) método para cicatrização de ferimentos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]